Bevacizumab does not increase risk of perforation in patients undergoing percutaneous endoscopic gastrostomy or jejunostomy placement.

Dibba, Pratima; Ludwig, Emmy; Calo, Delia; Gerdes, Hans; Markowitz, Arnold; Shike, Moshe; Schattner, Mark; Mendelsohn, Robin

Dibba, Pratima; Ludwig, Emmy; Calo, Delia; Gerdes, Hans; Markowitz, Arnold; Shike, Moshe; Schattner, Mark; Mendelsohn, Robin.

Afiliación

Dibba P; New York Presbyterian Brooklyn Methodist Hospital, New York, NY, USA.
Ludwig E; Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Calo D; Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Gerdes H; Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Markowitz A; Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Shike M; Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Schattner M; Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Mendelsohn R; Gastroenterology, Hepatology and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. mendelsr@mskcc.org.

Surg Endosc ; 35(6): 2976-2980, 2021 06.

Article en En | MEDLINE | ID: mdl-32583069

Asunto(s)

Gastrostomía; Yeyunostomía; Bevacizumab/efectos adversos; Femenino; Humanos; Recién Nacido; Recurrencia Local de Neoplasia; Estudios Retrospectivos

Palabras clave

Bevacizumab; PEG; PEJ; Percutaneous endoscopic gastrostomy; Percutaneous endoscopic jejunostomy; Perforation

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Yeyunostomía / Gastrostomía Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Newborn Idioma: En Revista: Surg Endosc Asunto de la revista: DIAGNOSTICO POR IMAGEM / GASTROENTEROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google